Natural product-derived therapy for glucose homeostasis and TIIDM: Astaxanthin, isolated from green algae heaematococcus pluvialis, Pandalus, and Phaffia, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4, 26/June/2017, 11.58 pm

Natural product-derived therapy for metastasis: Artemisinin, one of the components of Artemisia Annua, inhibits the expression of IL-6/8, decreases the expression of down stream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 26/June/2017, 11.25 pm
June 26, 2017
Natural product-based therapy for Inflammatory bowel disease: Methyl Jasmonate (MeJA), isolated from Jasmine, decreases the expression of oncostatin M, attenuates activation of oncostatin M- oncostatin M receptor pathway in inflamed colon tissues, inhibits inflammatory gene expression, attenuates colonic pathogenesis, and inhibits the progression of inflammatory bowel disease and colitis via down regulation of its target gene, 27/June/2017, 12.23 am
June 26, 2017
Show all

Introduction: What they say

Nobel laureate in Physiology/Medicine (1975) Prof. David Baltimore and his research team, from California Institute of Technology, California, USA, had reported in the September 14, 2014 issue of the Journal “Journal of Experimental Medicine (JEM)” that: “The microRNA-212/132 cluster regulates B cell development by targeting Sox4.”

Subsequently, Prof. Rorsman’s research team, from Oxford Centre for Diabetes, Endocrinology & Metabolism, Radcliffe Department of Medicine, Oxford, U.K; Department of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden Oxford; and National Institute of Health Research, Biomedical Research Centre, Churchill Hospital, Oxford, U.K, had reported in the March 18, 2016 issue of the Journal “Diabetes” that Increased Expression of the Diabetes Gene SOX4 Reduces Insulin Secretion by Impaired Fusion Pore Expansion.”


What we say:

On the foundation of these interesting findings, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for glucose homeostasis and TIIDM: Astaxanthin, isolated from green algae heaematococcus pluvialis, Pandalus, and Phaffia,  inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4

price-300

[easy_payment currency=”USD”]


From Significance of the study to Public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


From what is known to what we infer from what they say:

Prof. Rorsman’s research team has recently shown that overexpression of Sox4 results in: (1) increased expression of Amysin; (2) reduction in fusion pore size; (3) impairment of granule emptying; (4) impairment of insulin exit; (5) prevention of hormone release; and (6) reduction of glucose-induced insulin secretion, suggesting that decreasing the expression of Sox4 and its target gene Amysin in diabetic patients may alleviate TIIDM.


From Research findings to Therapeutic opportunity:

Figure1. Mechanistic insight into how Astaxanthin promotes insulin secretion.

Astaxanthin, by increasing the expression of its target genes, it may: (a) decrease the expression of exocytosis-regulating protein Amysin; and (b) increase the expression of PPARγ2 and A-FABP (fig.1).

Thereby, it may: (1) promote granule emptying and insulin release; and (2) increase glucose-induced-insulin secretion. Thus, pharmacological formulations encompassing Astaxanthin or its analogues, either alone or in combination with other drugs” may be used to treat TIIDM.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Astaxanthin decrease the expression of Amysin to increase insulin secretion?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Natural product-derived therapy for glucose homeostasis and TIIDM: Astaxanthin, isolated from green algae heaematococcus pluvialis, Pandalus, and Phaffia,  inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4 26/June/2017, 11.57 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.